Paul Thompson to Drug Design
This is a "connection" page, showing publications Paul Thompson has written about Drug Design.
Connection Strength
1.174
-
Subramanian V, Knight JS, Parelkar S, Anguish L, Coonrod SA, Kaplan MJ, Thompson PR. Design, synthesis, and biological evaluation of tetrazole analogs of Cl-amidine as protein arginine deiminase inhibitors. J Med Chem. 2015 Feb 12; 58(3):1337-44.
Score: 0.434
-
Obianyo O, Causey CP, Jones JE, Thompson PR. Activity-based protein profiling of protein arginine methyltransferase 1. ACS Chem Biol. 2011 Oct 21; 6(10):1127-35.
Score: 0.343
-
Muth A, Subramanian V, Beaumont E, Nagar M, Kerry P, McEwan P, Srinath H, Clancy K, Parelkar S, Thompson PR. Development of a Selective Inhibitor of Protein Arginine Deiminase 2. J Med Chem. 2017 04 13; 60(7):3198-3211.
Score: 0.126
-
Foyn H, Jones JE, Lewallen D, Narawane R, Varhaug JE, Thompson PR, Arnesen T. Design, synthesis, and kinetic characterization of protein N-terminal acetyltransferase inhibitors. ACS Chem Biol. 2013; 8(6):1121-7.
Score: 0.096
-
Jones JE, Causey CP, Knuckley B, Slack-Noyes JL, Thompson PR. Protein arginine deiminase 4 (PAD4): Current understanding and future therapeutic potential. Curr Opin Drug Discov Devel. 2009 Sep; 12(5):616-27.
Score: 0.075
-
Luo Y, Knuckley B, Lee YH, Stallcup MR, Thompson PR. A fluoroacetamidine-based inactivator of protein arginine deiminase 4: design, synthesis, and in vitro and in vivo evaluation. J Am Chem Soc. 2006 Feb 01; 128(4):1092-3.
Score: 0.058
-
Funabashi K, Sawata M, Nagai A, Akimoto M, Mashimo R, Takahara H, Kizawa K, Thompson PR, Ite K, Kitanishi K, Unno M. Structures of human peptidylarginine deiminase type III provide insights into substrate recognition and inhibitor design. Arch Biochem Biophys. 2021 Sep 15; 708:108911.
Score: 0.042